Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of alternating weekly temozolomide for leptomeningeal carcinomatosis from solid tumors
2005-005143-26Phase 2Active
- Sponsor
- Genom
- Start
- Feb 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in Carcinomatous Meningitis (CM), breast cancer, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Genom. Primary endpoints: Response rate and Time to progression. Started Feb 2006; status: active.
02
Drugs
temozolomide
03
Conditions
Carcinomatous Meningitis (CM)breast cancernon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on 2005-005143-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005143-26.